🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to present this work at #GU25 ASCO looking at the role and interplay of digital path AI and genomics.

🔬 Explore new data from ASCO #GU25 demonstrating the power of the #Decipher tests to improve patient care and our GRID tool to advance prostate and bladder cancer research. 📊 Learn more at Veracyte.com - investor.veracyte.com/news-releases/…

📊 At #EAU25, multiple abstracts showing the clinical performance of our #Decipher tests & independent performance data supporting our #MRD testing platform. investor.veracyte.com/news-releases/… Note regarding forward looking statements: veracyte.com/cautionary-not…

Findings from TOMBOLA Trial presented at #EAU25: New data demonstrate accuracy of our whole-genome sequencing-based #MRD testing platform for muscle-invasive bladder cancer. investor.veracyte.com/news-releases/… #UrologicCancer #PrecisionMedicine Cautionary note - veracyte.com/cautionary-not…

The #Afirma mission is to provide accurate molecular insights to help physicians create the best treatment plan for patients with indeterminate thyroid nodules. In this video, Dr. Amir Harari, Endocrinology Associates, discusses a landmark case. ▶️vimeo.com/1040577274?sha…

📅 April 11: Free Webinar for HCPs on #biomarkertesting in early-stage #breastcancer with Living Beyond Breast Cancer . Learn about our #ProsignaAssay - the only test combining molecular subtypes, proliferation score & clinical factors into a 10-yr recurrence risk. lbbc.org/community/even…

Prasana Santhanam, MBBS, MD, Johns Hopkins University School of Medicine, offers insights into a study that evaluated the pre-operative mRNA expression of Sodium-Iodide Symporter (NIS) in over 47,000 FNA thyroid nodule samples using the #Afirma GSC. ▶️ vimeo.com/1040581377

🔬 This week at #AUA2025: 18 abstracts on our Decipher Prostate & Decipher Bladder tests. Data includes clinical trial results & cancer biology insights derived through use of the Decipher GRID research tool. Explore - investor.veracyte.com/news-releases/… Note - veracyte.com/cautionary-not…

📣 The #DecipherProstate Metastatic Genomic Classifier is now available to select clinical sites through an early access program, with broader availability in June 2025. #OncologyInnovation #PrecisionMedicine Learn more: investor.veracyte.com/news-releases/… Note: veracyte.com/cautionary-not…

Just Released: 2024 Afirma® Research Collection offering new diagnostic insights into thyroid disease and molecular profiling. Download your copy of the latest clinical evidence today: veracyte.com/afirma-2024-re… #ThyroidDiagnostics #MolecularPath #PrecisionMed

Today at #ESMOBreast25: 10-year OPTIMA PRELIM clinical outcomes presented. Findings show #Prosigna breast cancer assay better classified patients' risk of recurrence as compared to the test used to initially assign patients to treatment groups. Results from this early feasibility

Cleveland Clinic researchers shared Afirma GRID-based data identifying genomic signatures that could potentially predict which thyroid cancers are likely to be aggressive. Such signatures could ultimately – pending further study – help #Endocrinologists,  #EndocrineSurgeons &

Gustave Roussy launches Phase 3 UMBRELLA trial using Veracyte’s MRD testing platform. 1️⃣ Read the full press release – gustaveroussy.fr/en/presence-tu… 2️⃣ Explore our MRD testing platform – veracyte.com/mrd-technology/ #PrecisionOncology #CancerDiagnostics #ClinicalTrials

Advancing Urologic Cancer Care at #ASCO25: We're excited to announce multiple Decipher-focused abstracts will be presented this week in Chicago, delivering high-value insights for oncology professionals. 📊 Learn more about the new data on Decipher Prostate, Bladder, and GRID -

Our Veracyte team is thrilled to be at #ASCO25! Stop by booth #31107 to discover how our thyroid, prostate & bladder tests deliver high-value insights for cancer care. Multiple Decipher-focused abstracts were presented this week. If you missed the presentations, click on the

Prasana Santhanam, MBBS, MD, Johns Hopkins University School of Medicine, offers insights into a study that evaluated the pre-operative mRNA expression of Sodium-Iodide Symporter (NIS) in over 47,000 FNA thyroid nodule samples using #Afirma GSC. Watch 5-minute presentation:

NEW STUDY: published in European Urology Oncology suggests potential opportunities to reshape how patients with nonmetastatic prostate cancer are treated. Researchers conducted the largest whole-transcriptome analysis of nonmetastatic prostate cancer known to date—evaluating over

Decipher® Prostate Metastatic test is now available in the U.S. for patients with metastatic prostate cancer. Validated in over 90 peer-reviewed studies and 200K patients, this tissue-based test is a highly accurate predictor of: 🔹Metastatic progression 🔹 Prostate